

John P Plastaras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4749526/publications.pdf>

Version: 2024-02-01

117
papers

2,478
citations

218677

26
h-index

223800

46
g-index

119
all docs

119
docs citations

119
times ranked

3816
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 201-205.	1.3	2
2	Quantifying the impact of the COVID-19 pandemic on gastrointestinal cancer care delivery. <i>Cancer Reports</i> , 2022, 5, e1427.	1.4	6
3	Activity Monitoring for Toxicity Detection and Management in Patients Undergoing Chemoradiation for Gastrointestinal Malignancies. <i>JCO Oncology Practice</i> , 2022, 18, e896-e906.	2.9	1
4	Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of SÅ©zary Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 90.	4.1	9
5	Early Cardiac Effects of Contemporary Radiation Therapy in Patients With Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1301-1310.	0.8	9
6	Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 201-211.	0.8	4
7	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 220-230.	0.8	7
8	Early Changes in Physical Activity and Quality of Life With Thoracic Radiation Therapy in Breast Cancer, Lung Cancer, and Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 946-952.	0.8	7
9	The efficacy and safety of definitive concurrent chemoradiotherapy for non-€operable esophageal cancer. <i>Cancer Medicine</i> , 2021, 10, 1275-1288.	2.8	3
10	Palliative Radiotherapy for Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 650-658.	0.4	6
11	Effect of activity monitoring on quality of life in patients with gastrointestinal cancer undergoing chemoradiation.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18671-e18671.	1.6	1
12	Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 671514.	2.8	4
13	Concurrent Nab-paclitaxel and Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 469-474.	1.3	4
14	Low-Dose Radiotherapy Versus Moderate-Dose Radiotherapy for the Treatment of Indolent Orbital Adnexal Lymphomas. <i>Frontiers in Oncology</i> , 2021, 11, 716002.	2.8	5
15	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6580-6590.	7.0	15
16	Multi-institutional Comparison of Intensity Modulated Photon Versus Proton Radiation Therapy in the Management of Squamous Cell Carcinoma of the Anus. <i>Advances in Radiation Oncology</i> , 2021, 6, 100744.	1.2	4
17	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 36-44.	0.8	6
18	PET/CT Responses in Primary Mediastinal Large B-Cell Lymphoma: What's Negative?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 595-596.	0.8	0

#	ARTICLE	IF	CITATIONS
19	CAR-T Cell Therapy for Lymphoma: How Does Radiation Therapy Fit In?. <i>Practical Radiation Oncology</i> , 2020, 10, e155-e158.	2.1	8
20	Cherenkov imaging for total skin electron therapy (TSET). <i>Medical Physics</i> , 2020, 47, 201-212.	3.0	22
21	Making Every Single Gray Count: Involved Site Radiation Therapy Delineation Guidelines for Hematological Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 279-281.	0.8	4
22	Management and outcomes of sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	8
23	ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 977-978.	0.8	1
24	Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. <i>Seminars in Radiation Oncology</i> , 2020, 30, 253-261.	2.2	18
25	Proton beam re-irradiation for gastrointestinal malignancies: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 187-202.	1.4	5
26	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. <i>Blood</i> , 2020, 135, 2365-2374.	1.4	30
27	Navigating the narrow bridge to CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 2884-2885.	5.2	13
28	Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 178-188.	0.8	60
29	Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 31-32.	1.4	0
30	Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 90-95.	0.8	20
31	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1464.	7.1	28
32	Keeping Our Finger on the Pulse: Reaffirming the Role of Radiation Therapy in the Curative Management of Early Stage Follicular Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 459-465.	0.8	2
33	Treatment specific toxicities: Hormones, antihormones, radiation therapy. <i>Seminars in Oncology</i> , 2019, 46, 414-420.	2.2	7
34	Don't Get Stuck on the Shoulder: Radiation Oncologists Should Get Into the CAR With T-Cell Therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1022-1024.	0.8	2
35	Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade. <i>Neuro-Oncology Practice</i> , 2019, 6, 297-304.	1.6	12
36	Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 851-860.	0.8	53

#	ARTICLE	IF	CITATIONS
37	A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy. <i>Blood</i> , 2019, 134, 4108-4108.	1.4	14
38	Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients. <i>Blood</i> , 2019, 134, 2905-2905.	1.4	2
39	A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 609-614.	2.3	8
40	Lower Gastrointestinal Malignancies. <i>Practical Guides in Radiation Oncology</i> , 2018, , 257-269.	0.1	0
41	Mediastinal Lymphoma. <i>Practical Guides in Radiation Oncology</i> , 2018, , 369-380.	0.1	0
42	Primary Liver Tumors: Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Practical Guides in Radiation Oncology</i> , 2018, , 95-127.	0.1	0
43	Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1118-1124.	1.3	32
44	FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, e139-e141.	1.3	1
45	Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 40-46.	1.0	9
46	Comparative Effectiveness of Neoadjuvant Chemoradiation Versus Upfront Surgery in the Management of Recto-Sigmoid Junction Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e557-e568.	2.3	2
47	Tolerability of sequential immune therapy and palliative radiotherapy to the cervical and thoracic spine. <i>Journal of Radiation Oncology</i> , 2018, 7, 233-239.	0.7	2
48	Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. <i>Advances in Radiation Oncology</i> , 2018, 3, 154-162.	1.2	11
49	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. <i>Blood</i> , 2018, 132, 1635-1646.	1.4	86
50	Radiotherapeutic Management of Lymphomas. , 2018, , 939-949.		0
51	Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1131-1142.	1.1	36
52	A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 1363-1371.	4.1	18
53	Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 825-842.	0.8	66
54	A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma. <i>Radiation Therapy and Oncology</i> , 2017, 124, 271-276.	0.6	30

#	ARTICLE	IF	CITATIONS
55	Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 281-292.	1.1	82
56	Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 665-674.	1.4	23
57	Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States. <i>Annals of Surgery</i> , 2016, 263, 298-305.	4.2	25
58	Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States. <i>Annals of Surgical Oncology</i> , 2016, 23, 2936-2945.	1.5	19
59	Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment. <i>Acta Oncologica</i> , 2016, 55, 1132-1138.	1.8	31
60	ACR Appropriateness Criteria® Hodgkin Lymphoma-“Unfavorable Clinical Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 384-395.	1.3	3
61	ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 535-544.	1.3	4
62	A Prospective Study of Proton Beam Reirradiation for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 483-487.	0.8	41
63	Modeling Long-Term Survival in Chemotherapy-Only Versus Combined Modality Therapy in Patients with Early Stage Unfavorable Hodgkin Lymphoma Involving the Mediastinum. <i>Blood</i> , 2016, 128, 2356-2356.	1.4	0
64	ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. <i>Oncology</i> , 2016, 30, 1099-103, 1106-8.	0.5	2
65	Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 531-541.	4.9	18
66	ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	1.3	9
67	Comparative Assessment of Liver Tumor Motion Using Cine-“Magnetic Resonance Imaging Versus 4-Dimensional Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 1034-1040.	0.8	34
68	Adjuvant Radiation Therapy Treatment Time Impacts Overall Survival in Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 326-336.	0.8	15
69	Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. <i>Practical Radiation Oncology</i> , 2015, 5, 209-218.	2.1	53
70	Radiation Oncology Resident In-Training Examination. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 532-535.	0.8	7
71	Pencil-beam scanning proton therapy for anal cancer: a dosimetric comparison with intensity-modulated radiotherapy. <i>Acta Oncologica</i> , 2015, 54, 1209-1217.	1.8	30
72	The role of ¹⁸F-FDG PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. <i>Cancer Medicine</i> , 2015, 4, 7-15.	2.8	18

#	ARTICLE	IF	CITATIONS
73	Consolidative Radiation Therapy Following Autologous Transplantation in Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 3195-3195.	1.4	2
74	Proton therapy in adjuvant treatment of gastric cancer: Planning comparison with advanced x-ray therapy and feasibility report. <i>Acta Oncologica</i> , 2014, 53, 1312-1320.	1.8	16
75	Special Cases for Proton Beam Radiotherapy: Re-irradiation, Lymphoma, and Breast Cancer. <i>Seminars in Oncology</i> , 2014, 41, 807-819.	2.2	30
76	Outcomes After Involved-field Radiation Therapy (IFRT) With or Without Rituximab in Patients With Early-stage Low-grade Non-Hodgkin Lymphoma (NHL) Staged With CT and PET. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 35-40.	1.3	1
77	Gastrointestinal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 378-386.	2.0	7
78	Clinical utility of integrated positron emission tomography/computed tomography imaging in the clinical management and radiation treatment planning of locally advanced rectal cancer. <i>Practical Radiation Oncology</i> , 2014, 4, 226-232.	2.1	15
79	Stage Migration in Planning PET/CT Scans in Patients Due to Receive Radiotherapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 79-85.	2.6	61
80	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	1.8	16
81	Melphalan/Total Body Irradiation-Conditioned Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients With Primary Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e225-e228.	0.4	8
82	A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas. <i>Medical Physics</i> , 2014, 41, 081711.	3.0	50
83	The impact of stool and gas volume on intrafraction prostate motion in patients undergoing radiotherapy with daily endorectal balloon. <i>Radiotherapy and Oncology</i> , 2014, 112, 89-94.	0.6	18
84	In Regard to Morris. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 240-241.	0.8	0
85	Proton Reirradiation of Recurrent Rectal Cancer: Dosimetric Comparison, Toxicities, and Preliminary Outcomes. <i>International Journal of Particle Therapy</i> , 2014, 1, 2-13.	1.8	30
86	Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1485-1491.	2.3	10
87	Radiotherapeutic Management of Lymphomas. , 2013, , 1015-1025.		0
88	Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective. <i>Leukemia and Lymphoma</i> , 2013, 54, 2168-2176.	1.3	14
89	The impact of radiation therapy sequencing on survival and cardiopulmonary mortality in the combined modality treatment of patients with esophageal cancer. <i>Cancer</i> , 2013, 119, 1976-1984.	4.1	11
90	Diffusely Metastatic Digital Papillary Adenocarcinoma 11 Years After Initial Presentation Treated With Palliative Chemotherapy and Radiotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, e386-e389.	1.6	11

#	ARTICLE	IF	CITATIONS
91	Abdominal and pancreatic motion correlation using 4D CT, 4D transponders, and a gating belt. Journal of Applied Clinical Medical Physics, 2013, 14, 13-24.	1.9	5
92	Radiation Therapy In Peripheral T-Cell Lymphoma Of The Head and Neck. Blood, 2013, 122, 1795-1795.	1.4	2
93	The Role Of PET Imaging For Predicting Treatment Failure In Primary Mediastinal B-Cell Lymphoma. Blood, 2013, 122, 4302-4302.	1.4	2
94	Risk Factors For Radiation Pneumonitis In Patients With Lymphoma Treated With Chemotherapy and Photon Or Proton Radiotherapy. Blood, 2013, 122, 5101-5101.	1.4	0
95	The Case for Combined-Modality Therapy for Limited-Stage Hodgkin's Disease. Oncologist, 2012, 17, 1006-1010.	3.7	4
96	Commentary. Neurosurgery, 2012, 71, E1062-E1063.	1.1	0
97	Feasibility of Electromagnetic Transponder Use to Monitor Inter- and Intrafractional Motion in Locally Advanced Pancreatic Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2012, 83, 566-573.	0.8	22
98	A Study to Quantify the Effectiveness of Daily Endorectal Balloon for Prostate Intrafraction Motion Management. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1055-1063.	0.8	51
99	The Use of PET in Radiation Therapy for Lymphoma. PET Clinics, 2012, 7, 67-72.	3.0	1
100	An evidence based review of proton beam therapy: The report of ASTRO's emerging technology committee. Radiotherapy and Oncology, 2012, 103, 8-11.	0.6	212
101	Real-Time Study of Prostate Intrafraction Motion During External Beam Radiotherapy With Daily Endorectal Balloon. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1302-1309.	0.8	62
102	Daily Isocenter Correction With Electromagnetic-Based Localization Improves Target Coverage and Rectal Sparing During Prostate Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1092-1099.	0.8	20
103	A one, two punch for liver cancer: Anti-angiogenesis with a death receptor agonist. Cancer Biology and Therapy, 2009, 8, 474-475.	3.4	1
104	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative <i>in vivo</i> effects against glioblastoma multiforme cells. Molecular Cancer Therapeutics, 2009, 8, 3285-3295.	4.1	33
105	Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients. Journal of Gastroenterology, 2009, 44, 84-91.	5.1	21
106	Improved Patient and Regimen Selection in Locally Advanced Rectal Cancer: Who, How, and What Next?. Clinical Colorectal Cancer, 2009, 8, 194-199.	2.3	6
107	Stage-Specific Survival Differences Associated with Postoperative Radiotherapy for Gastrointestinal Cancers. Journal of Gastrointestinal Cancer, 2008, 39, 86-99.	1.3	4
108	Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biology and Therapy, 2008, 7, 2047-2053.	3.4	24

#	ARTICLE	IF	CITATIONS
109	Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma. <i>Oncologist</i> , 2008, 13, 655-656.	3.7	4
110	Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. <i>Cancer Biology and Therapy</i> , 2008, 7, 628-635.	3.4	43
111	Cell Cycle-Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation. <i>Cancer Research</i> , 2007, 67, 9443-9454.	0.9	125
112	Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death. <i>Cancer Cell</i> , 2007, 12, 66-80.	16.8	241
113	Combination therapy with gemcitabine and 5-fluorouracil: Unblocking the pathways to survivin?. <i>Cancer Biology and Therapy</i> , 2006, 5, 1566-1568.	3.4	0
114	Paget's Disease of the Nipple as Local Recurrence After Breast-Conservation Treatment for Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 349-353.	2.4	15
115	Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. <i>Cancer Biology and Therapy</i> , 2005, 4, 1068-1074.	3.4	17
116	Xenobiotic-metabolizing Cytochromes P450 Convert Prostaglandin Endoperoxide to Hydroxyheptadecatrienoic Acid and the Mutagen, Malondialdehyde. <i>Journal of Biological Chemistry</i> , 2000, 275, 11784-11790.	3.4	66
117	Reactivity and Mutagenicity of Endogenous DNA Oxopropenylating Agents: α Base Propenals, Malondialdehyde, and N^6 -Oxopropenyllysine. <i>Chemical Research in Toxicology</i> , 2000, 13, 1235-1242.	3.3	80